Bionomics has announced that further data analysis of its phase 2 post traumatic stress disorder (PTSD) trial demonstrated the potential for significant patient benefit when drug exposure is adequate.
Pfizer and Merck have announced that Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival (PFS) in renal carcinoma study.
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).
Boehringer Ingelheim (Canada) and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials.
Gilead Sciences has announced topline data from the phase 3 Stellar-4 study of its liver disease treatment selonsertib in compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).
NeoTX Therapeutics has entered into a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox in combination with IMFINZI (durvalumab).
Moderna has announced the dosing of the first subject in a phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.
Eisai and Purdue Pharma announced six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.
Verseon has started dosing of its lead blood thinner candidate VE-1902 in a phase 1 trial held in healthy volunteers at Nucleus Network in Melbourne, Australia.
Newron Pharmaceuticals has announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.